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The aim of our study was to design a novel two-component hybrid scaffold using the fibrin/alginate porous 
hydrogel Smart Matrix® combined to a backing layer of plasma polymerised polydimethylsiloxane (Sil) 
membrane to make the fibrin-based dermal scaffold more robust for the treatment of the clinically challenging 
pressure sores. A design criteria was established, according to which the Sil membranes were punched to avoid 
collection of fluid underneath. Manual peel test showed that native silicone did not attach to the fibrin/alginate 
component while the plasma polymerised silicone membranes were firmly bound to fibrin/alginate. Structural 
characterisation showed that the fibrin/alginate matrix was intact after addition of the Sil membrane. By adding 
a Sil membrane to the original fibrin/alginate scaffold the resulting two-component scaffolds had a significantly 
higher shear or storage modulus G’. In vitro cell studies showed that dermal fibroblasts remained viable, 
proliferated and infiltrated the two-component hybrid scaffolds during the culture period. Our results show that 
the design of a novel two-component hybrid dermal scaffold was successful according to our proposed design 
criteria. To the best of our knowledge, this is the first study that reports combination of a fibrin-based scaffold 
with a plasma-polymerised silicone membrane. 
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Chronic pressure sores are challenging wounds which do not progress through the wound healing paradigm and 
are stuck in one of the healing phases. They are estimated to consume a major portion of the world healthcare 
budget and resources.[1] In the UK alone, the occurrence of pressure sores has been estimated to be around 1 in a 
100 people, costing approximately £400 million per annum. The prevalence of pressure sores has been shown to 
increase with age and is more common in women.[2,3] These wounds affect localised areas usually over a bony 
prominence e.g. the lower back and the buttocks, which are subjected to high pressure, shear and/or friction.[4] 
Similarly, pressure sores also affect amputees at the stump-socket interface, impacting the quality of life for 
these patients.[5,6] The current therapies to treat pressure sores, include debridement, controlling infection, 
compression bandages and negative pressure therapy to facilitate healing, and surgical intervention which are 
costly and ineffective in terms of healing the wound.[7] Therefore, these wounds present a major clinical 
challenge due to the lack of effective therapies and the continuing rise in the average age of the population.[8]     
 
Over the years, biomaterials have demonstrated a great potential in the treatment of full thickness skin 
wounds.[8,9] Modern tissue engineering principles involve designing biodegradable three-dimensional (3D) 
porous scaffolds that allow cell infiltration and diffusion of nutrients and oxygen. In addition to this, for the 
treatment of pressure sores the tissue-engineered scaffolds should be able to withstand pressure, shear and/or 
friction when applied on areas such as the lower back and buttocks.[10] Over the years, a range of scaffolds has 
been designed for the treatment of pressure sores either for use by themselves or as carriers for various 
components (growth factors, bioactive molecules and different types of cells) into the wound site. These 
scaffolds can be naturally derived from autologous and cadaveric sources or be synthetically manufactured.[11] 
Natural protein-based polymers such as fibrin or collagen are widely used as scaffold materials due to enhanced 
biocompatibility and bioactive properties. In order to improve their mechanical properties they are usually 
combined with synthetic polymers to form composites.[12-15] 
 
Silicones ([R2SiO]n; where R represents organic groups such as methyl, ethyl, or phenyl), also known as 
polymerized siloxanes or polysiloxanes, are synthetic polymers widely used in the biomedical field as solid 
support (in various shapes) with different bioactive materials (e.g. proteins, nucleic acids) immobilized on the 
surfaces.[16-18] Their first documented use as a bio-implant was by Lahey in 1946 who developed elastomeric 
silicone ‘bouncing clay’ to facilitate bile duct repair and stated that “it is flexible, it will stretch, it will bounce 
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like rubber and it can be cast in any shape”,[19] ideal properties for an implant. In addition to medical devices 
including pacemakers and catheter components,[20] silicones are also utilised in a variety of pharmaceutical 
applications including drug delivery systems.[21,22] Although silicones offer excellent strength and ductility, they 
are bioinert due to their physiochemical and morphological nature.[23] However, polymeric surfaces including 
silicones can be modified to introduce specific functional groups such as amine, imine, carboxyl, hydroxyl, 
isocyanate and expoxy, which facilitate the immobilization of biomacromolecules, e.g. proteins, and the 
interaction of the resulting surfaces with cells. Monomers can be bound onto polymeric surfaces under the 
influence of plasma through a relatively simple one-step coating process called plasma polymerization.[24-26]  
 
When designing hybrid composites of protein-based and synthetic polymers it is important to maintain the 
overall biocompatibility of the composite with the target tissue but also between the two different polymers to 
improve the overall efficiency of the biomaterial.[14,27] In our previous research we developed a 3-step method 
based on a quick, sensitive and robust immuno-based assay to determine the interfacial binding strength of 
proteins on synthetic polymeric surfaces.[28] Results using different plasma polymerised silicone surfaces –
poly(acrylic acid) and poly(allylamine)- showed that fibrinogen bound with a stronger affinity to plasma 
polymerised surfaces than to the native silicone.[28] Finally, a simple in vitro 2D cell culture model confirmed 
the biocompatibility of the plasma polymerised silicone surfaces.[28] 
 
Over the past decade our laboratory has developed a novel dermal replacement scaffold composed mainly of 
fibrin with alginate as a filler component.[29,30] The scaffold is branded Smart Matrix® and is at the 
commercialisation stage for the treatment of acute full thickness skin wounds such as third degree burns or acute 
surgical wounds. Smart Matrix® is a porous hydrogel that possesses an open, interconnected porous structure 
with a micro-pore size distribution ideal for skin regeneration.[29] Moreover, the material behaves like a 
viscoelastic solid, like skin and dermis tissues, and presents nano-features.[29] In vitro cell studies suggest that a 
higher influx of cells, reduced wound contraction and less scarring would be observed in vivo for Smart 
Matrix® when compared to similar acellular commercially available dermal scaffolds, namely Integra® and 
Matriderm®.[30] 
 
The aim of this study was to design a novel two-component hybrid scaffold using the fibrin-based dermal 
replacement scaffold Smart Matrix® with plasma polymerised polydimethylsiloxane (Sil) membrane as a 
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backing to make the fibrin-based scaffold more robust for the treatment of pressure sores. Plasma 
polymerization was used to add specific functional groups to the otherwise bioinert Sil. Acrylic acid and 
allylamine were used as monomers to generate thin layers rich in carboxyl (-COOH) and amine (-NH2) groups 
making the Sil surface highly branched and cross-linked, to facilitate the immobilization of biomacromolecules 
(fibrin and alginate in this study) and improve their adherence onto solid surfaces. The design criteria were: 1) 
Sil membranes should be punched to avoid collection of fluid underneath the membrane which could lead to 
oedema in vivo, 2) the Sil membrane should be firmly bound to the fibrin/alginate component, 3) the thickness 
of the two-component hybrid scaffolds should not be significantly greater than that of the fibrin/alginate 
scaffold, 4) the open and interconnected porous structure of the fibrin/alginate component should be maintained 
after adding the Sil membrane, 5) addition of a Sil membrane should significantly increase the shear modulus of 
elasticity (G’) compared to that of the fibrin/alginate component, 6) cell viability and growth properties on the 
hybrid scaffolds should be similar to those on the fibrin/alginate component, and 7) cell ingress and integration 
on the hybrid scaffold should be similar to those on the fibrin/alginate component. The overall hypothesis of this 
study was that addition of a plasma polymerised Sil membrane to the fibrin/alginate scaffold will add strength to 
the scaffold without affecting the architecture of the fibrin/alginate component and its cellular properties.   
 
2. Experimental Section 
2.1 Scaffold manufacture 
Polydimethylsiloxane membranes (~4.5 cm x ~4.5 cm; thickness = 70 µm) were punched with 1 mm diameter 
holes that were interspaced throughout the membrane (Fig. 1). Some of them were plasma polymerised with 
either acrylic acid or allylamine monomers to create thin hydrophilic layers of poly(acrylic acid) (AcA) or 
polyallylamine (AlA) coatings respectively (Altrika Ltd., UK). Fibrin/alginate porous hydrogels (Smart 
Matrix®) were manufactured from bovine fibrinogen using a foam-based method. Further chemical cross-
linking with glutaraldehyde and freeze/drying of the structure produced a ~2 mm thick white sheet that was 80-
90% porous with interconnected pores in the ideal range for cell infiltration and skin regeneration[29] (Fig. 1B). 
For manufacturing the hybrid two-component scaffold, the fibrin/alginate foam was cast on top of the Sil 
membranes prior to  chemical cross-linking and freeze-drying steps. Sil membranes were slightly smaller (~4.5 
cm x ~4.5 cm) than the fibrin/alginate hydrogel (~5 cm x ~5 cm) to be better able to observe the interface 





Figure 1. A) Scheme of the novel two-component hybrid dermal scaffold. B) Macroscopic photos of the 
different materials and hybrid scaffolds. C) Thickness of scaffolds presented as average ± standard deviation. 
 
 
2.2 Thickness of scaffolds 
Thickness of the different scaffolds was measured using a digital caliper. Scaffolds were held with forceps, the 
digital caliper was zeroed, and the outside jaws of the digital caliper adjusted to the edges of the scaffold, placed 
parallel to the jaws. Thickness was read in mm. Thickness of scaffolds was measured over 3 different randomly 
selected locations across the scaffold. Results were presented as average ± standard deviation.  
 
2.3 Scanning electron microscopy (SEM) 
Three scaffold per type of Sil membrane (manufactured in different batches) were imaged by SEM. Freeze/dried 
scaffolds were mounted on stubs, gold sputtered coated (Agar Auto Sputter Coater, Agar Scientific) and the 
cross-section and surface viewed (FEI Inspect F, Oxford Instruments, Oxford, UK).   
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2.4 Confocal scanning laser microscopy 
The 3D structure of the scaffolds was examined by confocal scanning laser microscopy using a Leica DM IRE2 
confocal microscope. Since SEM showed no structural variations across the different batches, 1 scaffold per 
type of Sil membrane from 1 batch was used. 5 mm x 5 mm pieces were cut from 3 different randomly selected 
locations across the scaffold. The auto-fluorescence of the scaffolds was detected using the 405 nm scanning 
laser. A total of 106 images were taken for Sil-AcA (9.7 µm step size), 91 images for Sil-AlA (9.7 µm step size) 
and 234 images for fibrin/alginate scaffold (Smart Matrix®) (5 µm step size) through the depth of the scaffolds. 
The depth of the z-stack was 1.02 mm for Sil-AcA, 837.2 µm for Sil-AlA and 1.17 mm for the fibrin/alginate 
scaffold. The confocal 3D z-stacks were processed using the Leica confocal software into maximum projection 
of the entire z-stack.  
 
2.5 Pore size distribution  
Pore size of the scaffolds was quantified from SEM images at 100X magnification, using ImageJ software 
(1.47v). The length of the scale bar on the SEM images was calculated and the distance in pixels was converted 
into the desired unit of length. Once the distance was set, the widest diameter of the pore was calculated and 
recorded. Pore size distribution was graphically represented by calculating the percentage of pore frequency 
over each scaffold. As with confocal microscopy, 1 scaffold per type of Sil membrane from 1 batch was used,  
with scaffolds cut into 5 mm x 5 mm pieces from 3 different randomly selected locations across the scaffold and 
one 100X image per location analysed. 
 
2.6 Rheology 
For this study we used a Kinexus Rheometer (Malvern Instruments, UK) in an oscillatory mode. From each 
dermal scaffold 4 cm x 4 cm samples were cut (n=3 per type of Sil membrane) and placed between two 20 mm 
diameter parallel plates (gap between plates=0.3 mm). The sample was hydrated and an integrated temperature 
controller was used to maintain the temperature of the sample stage at 20°C. A combined measurement 
including an ‘amplitude sweep’ and a ‘frequency sweep’ was carried out on each sample. The ‘amplitude 
sweep’ was performed by applying controlled stresses that were linearly increased from 0.1 to 10 %. Strains 
corresponding to the stresses were recorded. The oscillatory frequency was maintained at 1 Hz. The maximum 
strain within the linear viscoelastic region (LVER) was chosen from the ‘amplitude sweep’. Log G′ or Log G″ 
was plotted against strain to obtain a rheological spectrum.  
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2.7 Cell culture 
Cell experiments were performed using subcultures established from frozen stocks of primary normal human 
dermal fibroblasts (pnHDF), which were isolated from samples of normal human skin, obtained with donor 
consent and approved by local ethics committee. pnHDF cultures were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, 31885-023, Gibco, Paisley, UK) supplemented with 10 % fetal bovine serum (10270-
106, Gibco, Paisley, UK), 100 U/ml Penicillin-Streptomycin (15140-122, Gibco, Paisley, UK), and 200 µM L- 
glutamine (25030-024, Gibco, Paisley, UK) at 37⁰C with 5% CO₂. Cell morphology was routinely monitored by 
phase-contrast-light microscopy, medium was changed every 3-4 days and cells were passaged once they 
reached confluence. Cells were used at passages 5 or 6.  
 
2.8 Cell seeding onto scaffolds 
Scaffold were cut into 6 mm diameter discs and sterilised with 70 % IMS, washed with PBS (14190-094, Gibco, 
Paisley, UK) and tightly placed in a flat bottomed-96 well plate. The scaffolds were seeded with either 2.5x10⁵ 
(live/dead and alamarBlue® assays) or 5x10⁵ (histology and electron microscopy) pnHDF in 50 µl medium. 
After seeding, 200 µl of supplemented DMEM was added per well and the plate was incubated for 2 hours at 
37⁰C with 5% CO₂ to allow cells to settle onto scaffold discs. pnHDF seeded scaffold discs were transferred 
into a 12 well plate after incubation and covered with 2 ml of supplemented DMEM per well and cultured over a 
7 day period at 37⁰C with 5% CO₂.   
 
2.9 Live/dead assay 
Seeded scaffolds were assessed for cell incorporation and viability using Live/Dead cell staining according to 
the manufacturer’s guidelines (Sigma), wherein live cells fluoresce green and dead cells fluoresce red. Briefly, 
scaffolds were washed in PBS prior to staining with the live/dead staining solution and then the staining 
procedure was performed in the dark for 30 minutes at 37°C and 5% CO2. Live and dead cells were visualized 
by fluorescence imaging and confocal microscopy (Leica DM IRE2 confocal microscope).  
 
2.10 alamarBlue® activity assay  
Seeded scaffolds were transferred to fresh 12 well plates before the assay to ensure that only the metabolic 
activity of cells in the scaffolds was measured. Each cell seeded scaffold was tested with 1 ml of a 10 % 
alamarBlue® (DAL1025, Invitrogen™, Paisley, UK) solution, made up in phenol free supplemented DMEM 
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(11880, Gibco, Paisley, UK) and incubated for 3 hours at 37⁰C with 5% CO₂.  The 1 ml test samples were 
placed into a cuvette (FB55147, Fisher Scientific, Loughborough, UK) and the absorbance  at 570 nm was read, 
following the manufacturer’s instructions, against air in a M550 double beam UV/ visible spectrophotometer 
(Spectronic Camspec Ltd, Garforth, UK).  The absorbance at 600 nm of the phenol-free DMEM was read and 
subtracted from the test sample absorbance to obtain the final absorbance value.  
 
2.11 Paraffin histology of cellularised scaffolds 
Cellular ingress into the dermal matrices was assessed by histological processing of cellularised scaffolds and 
haematoxylin and eosin (H&E) staining of cross-sections. After 4 or 7 days in culture, cellularised scaffolds 
were fixed in 4% paraformaldehyde, embedded in paraffin and 4 µm thick sections were cut for H&E staining. 
Stained sections were observed under light microscopy (Zeiss Axiophot, Zeiss, Jena, Germany) and 
photographed with a DC200 Leica digital camera and IC50 software. 
 
2.12 Field emission scanning electron microscopy (FESEM) of cellularised scaffolds  
FESEM was carried out on cellularised scaffolds at the last time point (day 7) of cell culture to observe 
interaction of cell layers with the material. Seeded scaffolds underwent processing prior to being observed by 
FESEM. The samples were fixed in 2.5% glutaraldehyde (AGR1011, Agar Scientific and UK) overnight. The 
fixed samples were then washed with 0.1 M sodium cacodylate buffer solution (Agar Scientific, UK) and then 
stained with 1% Osmium tetroxide (75632, Sigma-Aldrich, UK) in 0.1 M sodium cacodylate buffer for 45 
minutes. The samples were later washed with sodium cacodylate buffer and subsequently dehydrated with a 
series of industrial methylated spirit (IMS) (20% - 60%, increasing in 10% increments) and 90%, 96% and 
100% ethanol. Finally, the samples were left inside a fume hood in 100% ethanol to dry overnight. The samples 
were mounted onto metal stubs, coated with gold and palladium using the Gatan (model 681) high resolution ion 
beam coater before being observed using the JEOL field emission scanning electron microscope (JSM-7401F).  
 
2.13 Statistics 
A one-way analysis of variance (ANOVA) with a Holm-Sidak post-hoc analysis was carried out using Sigma 





3. Results and Discussion 
3.1 Manufacturing and Characterization of Two-Component Hybrid Scaffolds 
3.1.1 Macroscopic Appearance, Peel Test and Scaffold Thickness 
Two-component hybrid scaffolds were manufactured by casting the fibrin/alginate foam on top of different Sil 
membranes (native or plasma polymerised with either acrylic acid or allylamine monomers) and were 
crosslinked with glutaraldehyde. The cross-linked composite was freeze-dried and further tested for structural, 
mechanical and cellular properties. Figure 1B shows that the scaffolds were macroscopically white and 
homogenous. At the end of the freeze-drying process, native Sil did not attach to the fibrin/alginate layer and 
was peeled off easily by manual peeling (Fig. 1B). This observation agreed with our previously published 
results using a novel immuno-based assay suggesting weaker binding between native Sil and fibrinogen that can 
be attributed to the hydrophobic nature of the Sil polymer.[31] However, the combination of plasma polymerized 
Sil and fibrin/alginate formed a stable structure with the components attached to each other. In fact, it was not 
possible to detach the derivatised Sil membranes from the fibrin/alginate layer by manual peeling, 
demonstrating that the plasma polymerised Sil membranes firmly anchored to the fibrin/alginate component. 
This could be due to the hydrophilic plasma polymerized layer deposited on the Sil surface.[28] Furthermore, no 
air pockets between the plasma polymerised Sil membranes and the fibrin/alginate components were observed, 
suggesting uniform binding between the two components. Based on the peel test and the macroscopic 
observations, and following our design criteria, scaffolds made with native silicone were ruled out as unsuitable 
for the intended purpose. 
 
We also tested whether the addition of a Sil membrane would affect the thickness of the fibrin/alginate 
component which would not be desirable. The fibrin/alginate component (Smart Matrix®) has a thickness of ~2 
mm ideal for a dermal scaffold since human dermis is 1.5-3 mm thick.[32] Our results showed that the addition of 
a Sil membrane, which was 0.07 mm thick, did not significantly affect scaffold thickness (Fig. 1C), in 
accordance with our outlined design criteria.  
 
3.1.2 Structural Characterization 
SEM was used to investigate the attachment and integration of the two components of the hybrid scaffolds. 
Images obtained by SEM analysis show a scaffold composed of two layers: a dense plasma polymerised Sil 
layer attached to a porous fibrin/alginate layer (Fig. 2). Binding between the polymerized Sil layer and 
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fibrin/alginate layer seemed uniform for both the composites. As previously reported, one of the main features 
of the fibrin/alginate dermal scaffold Smart Matrix® is the presence of both nano-fibres and nano-pores, thus 
resembling the natural extracellular matrix (ECM) which cells are exposed to in vivo.[29,33] SEM suggests that 





Figure 2. Representative SEM images of scaffolds. White arrows point at the silicone membrane. Scale bars left 
to right are: Fibrin/alginate, 1 mm / 200 µm / 100 µm / 20 µm; Fibrin/alginate + AcA, 1 mm / 400 µm / 200 µm / 
20 µm; Fibrin/alginate + AlA, 1 mm / 400 µm / 200 µm / 20 µm. Images at 5000X (20 µm scale bar, far right 
column) show nano-pores and nano-fibres.  
 
 
Confocal microscopy showed no qualitative differences in terms of surface topography between the 
fibrin/alginate scaffold and the two-component hybrid ones (Fig. 3). Confocal microscopy images also showed 
consistent results in terms of structure for the 3 scaffolds: all scaffolds presented open and interconnected 





Figure 3. 3D confocal z-stacks of scaffolds. Green arrows point at 1 mm pores present in the silicone 
membranes. White arrows point at the edge between the silicone membrane and the fibrin/alginate component. 
Images on the right show surface topography graphs of the scaffolds. 
 
 
Pore size distribution data showed very similar patterns for the 3 scaffolds: all had the majority of their pores in 
the range of 0-150 µm (Fig. 4). The literature refers to 20-125 µm as the ideal pore size range for skin 
regeneration while 10-110 µm is considered the ideal pore size range for cell infiltration.[34] Moreover, having a 
distribution of pore sizes that represents the actual in vivo scenario found in native tissue is important since cells 




Figure 4. Pore size distribution in scaffolds. Results display average ± standard deviation. 
 
 
Results from the structural characterisation were very encouraging since one of the essential points in the design 
criteria of this study was to keep the open and interconnected porous structure of the fibrin/alginate component 
intact as our previous work has shown that the structure is ideal for skin regeneration.[29] The next step of our 
study was to carry out rheological analysis of the hybrid scaffolds. 
 
3.1.3 Rheology 
As mentioned in our introduction, pressure sores are localised injuries affecting the skin and/or underlying tissue 
usually occurring over a bony prominence.[4] They happen as a result of pressure, shear and/or friction.[4] 
Limited literature exists regarding quantification of these forces, with interface pressure being the main focus of 
research probably due to being easier to assess compared to shear and friction. Interface pressure is defined as 
the perpendicular force applied per unit of area between the body and the support surface.[4] No quantitative data 
for pressure existed until Kosiak published in 1959 and 1961 his canine and rat experiments, which involved 
loading tissues with known pressures for specific durations with histology used to assess tissue viability: 
damage was observed in tissues subjected to as little as 8 kPa for only one hour.[36,37] More recent mean peak 
interface pressure values were reported by Peterson and colleagues: 8.6 to 17.9 kPa depending on position and 
patient type (at-risk or non-disabled).[4] Values for shear forces measured at 5 specific sites in the body were 
reported by Mimura et al., where mean values ranged between ~2.5 to ~22 N.[38] The general consensus is that 
shear and pressure act in conjunction to produce the damage to skin and/or underlying tissues that results in a 
pressure sore. We previously reported the magnitude of the shear or storage modulus G’ for Smart Matrix® 
(average ± standard deviation = 8.26 ± 1.20 kPa),[29] which based on the values found in the literature for 
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interface pressure and shear would suggest that Smart Matrix® would not be strong enough to resist these 
forces. Hence, the aim of this work to combine it with a silicone membrane. 
 
Various properties of silicones make them favourable for biomedical uses, especially for wound dressings, 
including low liquid surface tension, high permeability, pressure-sensitivity, mechanical resistance and ease of 
sterilisation.[39] Moreover, there are several documented cases of using silicone to enhance the mechanical 
properties of more fragile biomaterials, especially in the case of wound dressings.[40-44] As an example, Pires and 
Moares demonstrated the enhanced tensile strength and flexibility of chitosan-alginate membranes following 
incorporation of the liquid silicone rubber Silpuran® 2130 A/B.[40] This may be attributed to several factors 
including cross-linking of the silicone polymer chains at various points in the chitosan-alginate membrane to 
form a more resistant structure.[40]  
 
In our study, the mechanical properties of the scaffolds were investigated by rheology, a branch of engineering 
that studies the viscoelastic properties (both solid and fluid) of materials as well as biological tissues.[29,45,46] 
Skin tissue has been described as a viscoelastic solid as under low magnitude oscillatory shear, as used in this 
study, its behaviour is primarily of an elastic nature.[45] Rheological analysis showed that the hybrid scaffolds 
had significantly higher shear and viscous moduli (G’ and G’’ respectively) than the original Smart Matrix® 
fibrin/alginate scaffold (Fig. 5). The shear or storage modulus G’ is related to elasticity and is an indication of 
how the material stores energy which can be re-used in the form of elastic deformation. Therefore, G’ relates to 
the solid characteristics of the material.[45-47] In our study, a higher G’ for the hybrid scaffolds means that they 
have a higher strength compared to the fibrin/alginate scaffolds.[47] Moreover, the hybrid scaffolds manufactured 
using Sil plasma polymerised with acrylic acid monomers had higher G’ and G’’ than scaffolds manufactured 
with Sil plasma polymerised with allylamine monomers, suggesting that hybrid scaffolds with a membrane of 
Sil plasma polymerised with acrylic acid monomers would have a higher strength than hybrid scaffolds with a 
membrane of Sil plasma polymerised with allylamine monomers. This could be due to increased binding 
strength of fibrinogen to poly(acrylic acid) surfaces compared to polyallylamine surfaces.[28] However, these 
differences were not significant. Furthermore, for all scaffolds G’>G’’ suggesting an elastic behaviour (solid) 
rather than viscous (fluid), also confirmed by the phase angle values which were closer to 0° (typical of elastic 
materials) than to 90° (typical of viscous materials).[45-47] Therefore, the scaffolds from this study could be 




In summary, the rheology results show that by adding a silicone membrane to the original fibrin/alginate 
scaffold (Smart Matrix®) the resulting two-component scaffolds are more robust and therefore, would be more 
suitable for application in the treatment of pressure sores compared to Smart Matrix®. The concept of the 
backing membrane is to protect the protein scaffold from tearing when placed on difficult wounds on the lower 











3.2 In vitro Cell Studies 
Scaffolds for tissue repair and regeneration are used as 3D structural templates to support the adhesion, 
proliferation, differentiation and migration of cells. Therefore, before implanting scaffolds into hosts it is 
essential to demonstrate their biocompatibility in vitro. In our previous studies, in vitro cell work has been 
carried out on the individual components of the novel hybrid scaffold designed in this study: the fibrin/alginate 
matrix (Smart Matrix®) and the plasma polymerised Sil layers.[28-30] In this study, in vitro cell work on the two-
component hybrid composite scaffold was carried out using primary human dermal fibroblasts, the main cell 
type found in the dermis.[48] Cell viability and growth were analysed by live/dead and metabolic (alamarBlue®) 
assays. Since the original fibrin/alginate Smart Matrix® has shown rapid infiltration of cells,[29,30] cell ingress 
into the scaffolds was also evaluated using histological processing and H&E staining. Finally, FESEM was used 
to investigate integration of cells with the material. 
 
3.2.1 Cell Viability and Growth 
Results showed that cells remained viable and proliferated through the culture period (Fig. 6). Metabolic activity 
was significantly higher on day 7 than on day 2 for all scaffolds (Fig. 6A), suggesting significant cell 
proliferation on the three scaffolds. Moreover, no significant differences were observed between the three 
scaffolds at any of the time points (Fig. 6A). These results suggest that cell viability and proliferation are not 






Figure 6. A) alamarBlue® metabolic assay over 7 days of culture. B) live/dead assay on day 7 showing viable 
cells on the three scaffolds: green colour (left) indicative of live cells and red colour (right) indicative of dead 
cells (scale bar = 500 µm). 
 
 
3.2.2 Cell Ingress 
Once a dermal scaffold is implanted, cells from the surrounding uninjured skin tissue migrate into the scaffold, 
proliferate, and start laying down a temporary collagen type III-rich ECM that will be later remodelled into a 
stronger collagen type I-rich ECM by matrix metalloproteinases that are secreted by fibroblasts, macrophages 
and endothelial cells.[49] Infiltration of cells into the scaffold is therefore critical for a successful outcome. Our 
previous research has suggested a high influx of cells into Smart Matrix®,[29,30] thus we wanted to determine 




Our results showed that cell infiltration into the hybrid scaffolds was very similar to the fibrin/alginate scaffold 
(Smart Matrix®), with cells populating the entire depth of the scaffolds after 4 days in culture (Fig. 7A). Higher 




Figure 7. Paraffin histology and H&E staining of seeded scaffolds at days 4 and 7 of culture. Fibrin/alginate 
matrix appears pink while cells are stained in purple colour. A) Scale bar = 100 µm and B) scale bar = 50 µm. 
The silicone membrane plasma polymerised with acrylic acid monomers came off after the histological 
processing and only traces of it could be seen. For the hybrid scaffold manufactured using polyallylamine 
silicone, the membrane was still present after the histological processing, although photos show that it was not 






3.2.3 Cell Integration 
To observe the interaction of pnHDF with the hybrid scaffolds, FESEM was used. Hybrid scaffolds seeded with 
pnHDF were subjected to FESEM at the last time point (day 7 of culture) and compared to the control 
fibrin/alginate scaffolds without any Sil membrane. The FESEM images showed good attachment of cells in all 
samples with cells embedded within the matrix (Fig. 8). These results demonstrate good interaction of dermal 
fibroblasts, the main cell type found in the dermis layer of skin,[48] with the fibrin/alginate component of the 




Figure 8. FESEM images of seeded scaffolds at day 7 of culture. *shows the nano-fibres and nano-pores present 
in the fibrin/alginate matrix. White arrows point at cells which are seen embedded in the matrix. For all images 
scale bar = 10 µm. 
 
 
Results from the in vitro cell studies showed that addition of a plasma polymerised Sil membrane to the 
fibrin/alginate scaffold did not have an effect in terms of cell viability, growth, ingress, and integration, in 
accordance with our design criteria. Moreover, results from our work pose the question of which plasma 
polymerised Sil membrane would be best for the two-component hybrid scaffold: poly(acrylic acid) or 
polyallylamine coating. The only difference found between both membranes was in the rheological 
characterisation; the hybrid scaffold manufactured with a poly(acrylic acid)-Sil membrane was found to be 
stronger than the one manufactured with a polyallylamine-Sil membrane (Fig. 5), although this difference was 
not significant. We believe that further in vivo work in a suitable animal model could help to answer this 
question. The Sil membrane is only intended as a temporary cover to protect the fibrin/alginate component from 
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the forces experienced in pressure ulcers. Therefore, the Sil membrane will be ultimately removed. In vivo work 
will also help to answer the question regarding removal of the membrane after implantation of the hybrid 
scaffold, since the fibrin/alginate component will start degrading in vivo as new dermal tissue is formed. 
 
The main strategy currently used in the treatment of pressure sores is relief of pressure using specialist support 
surfaces together with management of the wound environment using wound dressings. Moreover, pain 
management, optimising circulation/perfusion, patient education, nutrition, and the treatment of infection are 
applied. Signs of healing are expected within two weeks of initial treatment. However, in many instances 
improvement may not occur and deterioration is observed.[50]  Therefore, tissue engineering strategies have been 
explored as an alternative. Several tissue-engineered scaffolds have been applied for the treatment of pressure 
sores. Different types of tissue-engineered skin substitutes exist (animal derived, cellular and acellular) and they 
all offer advantages and disadvantages. Animal derived skin substitutes, i.e. OASIS Wound Matrix® 
(decellularised porcine jejunal submucosa) or MatriStem® UBM (porcine bladder-derived extracellular matrix), 
have been used to treat pressure sores as well as other chronic wounds such as venous and diabetic ulcers. The 
reported disadvantages of these products are rejection (main issue), infection and disease transfer.[3,51,52] Cellular 
skin substitutes such as Apligraf® (composite bilayered product consisting of living keratinocytes and 
fibroblasts derived from neonatal human foreskin in a bovine collagen gel matrix) or Dermagraft® 
(cryopreserved allogenic human neonatal foreskin fibroblast-derived bioabsorbable dermal matrix) have been 
used to treat chronic ulcers. However, these products are complex composites consisting of  living cells which 
adds to the biomaterials high cost, manufacturing difficulty and limited shelf-life.[53-55] Acellular skin substitutes 
eliminate the complexity and limited shelf-life of cellular products. The most commonly used acellular 
substitute is Integra®, which is composed of a temporary silicone epidermal substitute over a dermal scaffold 
made of bovine collagen type I and chondroitin-6-sulphate from shark cartilage.[29] Integra® has been used in 
the treatment of pressure sores with reported wound closure. However, the main disadvantage of using Integra® 
is a risk of infection due to the collection of fluid underneath the silicone layer.[8,56] Our proposed hybrid 
scaffold has a punched silicone membrane to allow fluid flow thus potentially eliminating the problems 
previously reported with Integra®. Another disadvantage of using Integra® is that it is not easily biodegradable 
and has been reported to stay in the body for up to 2 years after implantation, with an associated risk of 
inflammatory reaction.[57,58] An earlier study by our group showed that the fibrin/alginate matrix degrades faster 
than Integra®.[29] Faster degradation of our hybrid scaffolds can be argued to be a disadvantage in a chronic 
21 
 
environment, but the timeline of degradation can be optimized by varying different parameters depending on the 
depth of injury. Finally, our proposed hybrid scaffold is designed to address issues currently observed with the 




The aim of our study was to design a novel two-component hybrid scaffold using the fibrin/alginate porous 
hydrogel Smart Matrix® combined to a backing layer of plasma polymerised polydimethylsiloxane membrane 
to make the fibrin-based dermal scaffold more robust for the treatment of the clinically challenging pressure 
sores. Plasma polymerization was used to add specific functional groups to the otherwise bioinert Sil: acrylic 
acid or allylamine monomers were used to generate thin layers rich in carboxyl (-COOH) and amine (-NH2) 
groups making the Sil surface highly branched and cross-linked to facilitate the immobilization of 
biomacromolecules (fibrin in this study). A design criteria was established, according to which the Sil 
membranes were punched to avoid collection of fluid underneath which could lead to oedema in vivo. The 
fibrin/alginate porous hydrogel (Smart Matrix®) is manufactured using a foam-based method, so for 
manufacturing the hybrid scaffolds the fibrin/alginate foam was cast on top of the Sil membranes. Manual peel 
test showed that native silicone did not attach to the fibrin/alginate component while the plasma polymerised 
silicone membranes were firmly bound to the fibrin/alginate matrix. Structural characterisation showed that the 
fibrin/alginate matrix was intact (open and interconnected porous structure with micro-pores in an ideal range 
for cell infiltration and skin regeneration) after addition of the Sil membrane, in agreement with our design 
criteria. Rheology results showed that by adding a Sil membrane to the original fibrin/alginate scaffold (Smart 
Matrix®) the resulting two-component scaffolds had a significantly higher shear or storage modulus G’ making 
them stronger than the fibrin/alginate scaffold, and therefore, would be more suitable for the treatment of 
pressure sores in comparison to Smart Matrix® alone. In vitro cell studies showed that dermal fibroblasts 
remained viable, proliferated and infiltrated the scaffolds during the culture period. Our results show that the 
design of a novel two-component hybrid dermal scaffold was successful according to our proposed design 
criteria. To the best of our knowledge, this is the first study that reports combination of a fibrin-based scaffold 
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